<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of hyperprolactinemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of hyperprolactinemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of hyperprolactinemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lactotroph adenomas (prolactinomas) are more amenable to pharmacologic treatment than any other kind of pituitary adenoma because of the availability of dopamine agonists, which usually decrease both the secretion and size of these tumors. For the minority of lactotroph adenomas that do not respond to dopamine agonists, other treatments must be used. Hyperprolactinemia due to nonadenoma causes should also be treated if it causes hypogonadism.</p><p>This topic will review the major issues concerning the therapy of hyperprolactinemia due to lactotroph adenomas and other causes, with the exception of treatment during pregnancy, which is discussed separately. The causes, clinical manifestations, and diagnosis of hyperprolactinemia are also discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6629.html" rel="external">"Management of lactotroph adenoma (prolactinoma) before and during pregnancy"</a> and  <a class="medical medical_review" href="/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a> and  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia"</a>.)</p><p class="headingAnchor" id="H445458738"><span class="h1">INDICATIONS FOR TREATMENT</span><span class="headingEndMark"> — </span>There are two principal reasons why patients with hyperprolactinemia may need to be treated: existing or impending neurologic symptoms due to the large size of a lactotroph adenoma, and hypogonadism or other symptoms due to hyperprolactinemia, such as galactorrhea [<a href="#rid1">1-3</a>].</p><p>A third indication is in women with mild hyperprolactinemia and normal cycles who are trying to conceive as they may have subtle luteal phase dysfunction. (See  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia", section on 'Menstrual cycle dysfunction'</a>.)</p><p>Our approach to management is similar to that suggested by the Endocrine Society Guidelines [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H445458796"><span class="h2">Adenoma size</span><span class="headingEndMark"> — </span>A lactotroph adenoma (prolactinoma) 1 cm or more in size is a macroadenoma. Treatment is usually essential when the tumor is large enough to cause neurologic symptoms, such as visual impairment or headache (see  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses", section on 'Clinical manifestations'</a>). Treatment is usually desirable when the adenoma extends outside of the sella and abuts or elevates the optic chiasm, or invades the cavernous or sphenoid sinuses or the clivus; lesions of this size are likely to continue to grow and eventually cause neurologic symptoms.</p><p>Microadenomas are less than 1 cm in diameter. Studies of the natural history of microadenomas show that 95 percent do not enlarge during four to six years of observation [<a href="#rid4">4,5</a>]. The 5 percent that do enlarge should be treated because of the increase in size alone. (See <a class="local">'Withdrawal of dopamine agonists'</a> below.)</p><p>Prolactin secretion by lactotroph adenomas is usually proportional to their size. Adenomas &lt;1 cm in diameter are typically associated with serum prolactin values below 200 ng/mL (8.7 nmol/L), those approximately 1 to 2 cm in diameter with values between 200 and 1000 ng/mL (8.7 to 43.48 nmol/L), and those greater than 2 cm in diameter with values above 1000 ng/mL (43.48 nmol/L) and as high as 50,000 ng/mL (2173.91 nmol/L)  (<a class="graphic graphic_figure graphicRef72540" href="/d/graphic/72540.html" rel="external">figure 1</a>). There are exceptions to this generalization, however, as occasional patients have a large lactotroph adenoma but only modest hyperprolactinemia. Such adenomas are generally less well differentiated and respond less well to dopamine agonists than the more typical adenomas.</p><p>In contrast to the extremely high serum prolactin concentrations that may be seen with lactotroph macroadenomas, prolactin levels due to nonadenoma causes rarely exceed 200 ng/mL (8.7 nmol/L). (See  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia", section on 'Serum prolactin concentrations'</a>.)</p><p class="headingAnchor" id="H445458845"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Treatment of hyperprolactinemia is indicated when it causes hypogonadism by suppressing gonadotropin secretion or when it causes bothersome galactorrhea [<a href="#rid1">1</a>]. The clinical manifestations of hyperprolactinemia are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia"</a>.)</p><p class="headingAnchor" id="H1941798410"><span class="h3">Premenopausal women</span></p><p class="bulletIndent1"><span class="glyph">●</span>In premenopausal women, serum prolactin concentrations &gt;100 ng/mL (4.35 nmol/L) are likely to be associated with amenorrhea and low <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> levels (which lead to eventual bone loss and osteoporosis if untreated). The symptoms correlate with the magnitude of the hyperprolactinemia. Moderate degrees of hyperprolactinemia (eg, serum prolactin values of 50 to 100 ng/mL [2.17 to 4.35 nmol/L]) cause either amenorrhea or oligomenorrhea, and milder degrees of hyperprolactinemia (20 to 50 ng/mL [0.87 to 2.17 nmol/L]) may cause oligomenorrhea or not affect menses but cause infertility due to insufficient luteal phase <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> secretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperprolactinemia in premenopausal women can also cause galactorrhea. The presence of galactorrhea alone does not require treatment unless the patient finds it bothersome.</p><p></p><p class="headingAnchor" id="H2811660403"><span class="h3">Postmenopausal women</span></p><p class="bulletIndent1"><span class="glyph">●</span>Postmenopausal women have markedly low <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> levels due to cessation of ovarian function, and therefore, galactorrhea is rare. Hyperprolactinemia in these women is clinically recognized only in the unusual situation when a lactotroph adenoma becomes so large as to cause headaches or impair vision.</p><p></p><p class="headingAnchor" id="H48271787"><span class="h3">Men</span></p><p class="bulletIndent1"><span class="glyph">●</span>In men, hypogonadism can cause decreased libido and energy and eventually loss of sexual hair, loss of muscle mass, and osteoporosis. Hyperprolactinemia in men may also be associated with erectile dysfunction, even when the serum <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> concentration is normal. The mechanism is unknown, but the erectile dysfunction usually improves dramatically when the hyperprolactinemia is corrected [<a href="#rid6">6-8</a>]. Gynecomastia and galactorrhea may occur, but both are rare.</p><p></p><p class="headingAnchor" id="H361074044"><span class="h1">OVERVIEW OF DOPAMINE AGONISTS</span><span class="headingEndMark"> — </span>A dopamine agonist drug should usually be the first treatment for patients with hyperprolactinemia of any cause, including lactotroph adenomas (prolactinomas) of all sizes, because these drugs decrease serum prolactin concentrations and decrease the size of most lactotroph adenomas [<a href="#rid9">9,10</a>].</p><p>Other approaches must be considered for the minority of patients whose adenomas are resistant to dopamine agonists or who cannot tolerate these drugs, and for those who are taking a medication (such as an antipsychotic drug) that cannot be discontinued  (<a class="graphic graphic_algorithm graphicRef134594" href="/d/graphic/134594.html" rel="external">algorithm 1</a>). (See <a class="local">'Intolerant or inadequate response'</a> below and <a class="local">'Drug-induced hyperprolactinemia'</a> below.)</p><p class="headingAnchor" id="H1476255990"><span class="h2">Choice of drug</span><span class="headingEndMark"> — </span>For most patients with hyperprolactinemia, <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> is our first choice, and <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> is our second. Pergolide had been used for Parkinson disease and hyperprolactinemia, but it was withdrawn from the market in the United States because of concerns about valvular heart disease. <a class="drug drug_general" data-topicid="10227" href="/d/drug information/10227.html" rel="external">Quinagolide</a> is available in some countries, but not the United States. (See <a class="local">'Valvular heart disease'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cabergoline</strong> – We suggest <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> as the first choice because of its efficacy and favorable side-effect profile [<a href="#rid2">2</a>]. It is an ergot dopamine agonist that is administered once or twice a week and has much less tendency to cause nausea than <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> [<a href="#rid11">11,12</a>]. It may also be effective in patients resistant to bromocriptine [<a href="#rid13">13</a>]. At the high doses used for the treatment of Parkinson disease, cabergoline is associated with an increased risk of valvular heart disease [<a href="#rid14">14,15</a>], but at the lower doses generally used for the treatment of hyperprolactinemia, cabergoline does not appear to be associated with this risk or a lower risk. (See <a class="local">'Valvular heart disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bromocriptine</strong> – <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">Bromocriptine</a> is an ergot derivative that has been used for approximately four decades for treatment of hyperprolactinemia. It should be given twice a day to have optimal therapeutic effect [<a href="#rid9">9</a>]. It is more likely to cause nausea than <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pergolide</strong> – Pergolide is an ergot derivative that had been used primarily for the treatment of Parkinson disease [<a href="#rid16">16</a>]. At the high dose used for Parkinson disease (&gt;3 mg/day), pergolide was associated with an increased risk of valvular heart disease [<a href="#rid14">14,15</a>]. It was withdrawn from the United States market in 2007 [<a href="#rid17">17</a>], but it is still available in some countries. (See <a class="local">'Valvular heart disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – <a class="drug drug_general" data-topicid="10227" href="/d/drug information/10227.html" rel="external">Quinagolide</a> (CV 205-502), a non-ergot dopamine agonist that is given once or twice a day, is available in some countries but not the United States [<a href="#rid18">18-20</a>]. The starting dose is 0.075 mg once a day, which can be increased to twice a day and a maximum total daily dose of 0.9 mg. It is generally considered a second-line drug if <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> is available, but unlike cabergoline, it is not an ergot derivative so valvular heart disease is not a concern.</p><p></p><p class="headingAnchor" id="H361075294"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Dopamine agonists decrease prolactin secretion  (<a class="graphic graphic_figure graphicRef72539" href="/d/graphic/72539.html" rel="external">figure 2</a>) and reduce the size of the lactotroph adenoma  (<a class="graphic graphic_diagnosticimage graphicRef86088" href="/d/graphic/86088.html" rel="external">image 1</a>) in more than 90 percent of patients. Both effects are mediated by the binding of the drug to cell-surface dopamine receptors, leading to reductions in the synthesis and secretion of prolactin and in adenoma cell size [<a href="#rid21">21</a>]. A review of 13 studies, as an example, showed that <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> reduced the serum prolactin concentration to normal in 229 of 280 women (82 percent) with hyperprolactinemia, and in 12 studies, in 66 of 92 patients (71 percent) with lactotroph macroadenomas [<a href="#rid9">9</a>].</p><p><a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">Cabergoline</a> may be superior to <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> in decreasing the serum prolactin concentration [<a href="#rid11">11,13</a>]. This was illustrated in a trial of 459 women with hyperprolactinemia and amenorrhea who had microadenomas or no obvious cause; the patients who were randomized to cabergoline were more likely to have a reduction of serum prolactin to normal (83 versus 52 percent in the bromocriptine group)  (<a class="graphic graphic_figure graphicRef72539" href="/d/graphic/72539.html" rel="external">figure 2</a>) [<a href="#rid11">11</a>]. In addition, a meta-analysis of three trials and six observational studies reported that cabergoline was more effective than bromocriptine in reducing the risk of persistent hyperprolactinemia, amenorrhea, and galactorrhea (relative risk [RR] 2.88, 1.85, and 3.41, respectively) [<a href="#rid10">10</a>].</p><p>Overall, the greater the decrease in serum prolactin concentration, the greater the decrease in adenoma size, although there is considerable variation from patient to patient. The effect on adenoma size is most apparent in patients with lactotroph macroadenomas  (<a class="graphic graphic_diagnosticimage graphicRef86088" href="/d/graphic/86088.html" rel="external">image 1</a>) [<a href="#rid22">22</a>].</p><p>The therapeutic efficacy of dopamine agonists may be blunted by the concurrent use of drugs known to raise serum prolactin concentrations, including neuroleptic drugs, <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>, sulpiride, <a class="drug drug_general" data-topicid="8777" href="/d/drug information/8777.html" rel="external">domperidone</a>, <a class="drug drug_general" data-topicid="9635" href="/d/drug information/9635.html" rel="external">methyldopa</a>, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, and <a class="drug drug_general" data-topicid="9265" href="/d/drug information/9265.html" rel="external">cimetidine</a>.</p><p><a class="drug drug_general" data-topicid="10227" href="/d/drug information/10227.html" rel="external">Quinagolide</a> appears to have equivalent therapeutic effects to <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> in reducing serum prolactin and adenoma size [<a href="#rid19">19,23</a>]. It is available in some countries, but not the United States.</p><p class="headingAnchor" id="H361075490"><span class="h2">Time course of clinical response</span><span class="headingEndMark"> — </span>The fall in serum prolactin typically occurs within the first two to three weeks of therapy with a dopamine agonist  (<a class="graphic graphic_figure graphicRef72539" href="/d/graphic/72539.html" rel="external">figure 2</a>) [<a href="#rid11">11</a>]; in patients with macroadenomas, it always precedes any decrease in adenoma size [<a href="#rid19">19</a>]. The decrease in adenoma size can, in many patients, be detected by imaging within six weeks after initiation of treatment; in some patients, however, a decrease is not apparent for six months  (<a class="graphic graphic_diagnosticimage graphicRef86088" href="/d/graphic/86088.html" rel="external">image 1</a>) [<a href="#rid22">22</a>]. These benefits occur even in patients who have impaired visual fields before therapy, occurring in 9 of 10 such patients in each of two reports [<a href="#rid24">24,25</a>].</p><p>Following the decrease in serum prolactin and adenoma size in patients with macroadenomas, visual and pituitary function often return to normal. Vision usually begins to improve within days after the initiation of treatment [<a href="#rid22">22,24</a>]. There is recovery of menses and fertility in women and of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> secretion, sperm count, and erectile function in men [<a href="#rid9">9,11,26-28</a>]. Patients with macroadenomas who are hypothyroid and/or hypoadrenal may also have a return of these functions to normal [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H361075724"><span class="h2">Adverse effects</span></p><p class="headingAnchor" id="H2621166025"><span class="h3">Typical</span><span class="headingEndMark"> — </span>The principal side effects of dopamine agonist drugs are nausea, postural hypotension, and mental fogginess. Less common side effects include nasal stuffiness, depression, Raynaud phenomenon, alcohol intolerance, and constipation. Nausea appears to be more common with <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> than <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a>.</p><p>Side effects are more likely to occur when treatment is initiated or the dose is increased. They can be avoided in most patients by starting with a small dose (eg, one-half of the lowest strength pill of <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> once a day or half a pill of <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> twice a week) and by giving it with food or at bedtime. A small percentage of patients have side effects even at the lowest doses. In women, nausea can be avoided by intravaginal administration [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H1594896631"><span class="h3">Impulse control disorders</span><span class="headingEndMark"> — </span>An uncommon but well-recognized adverse effect is the onset or exacerbation of impulse control disorders, such as hypersexuality and compulsive gambling, shopping, or eating. These behaviors had originally been described in case reports. In a small, controlled study, 10 hyperprolactinemic patients who were treated with <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> had a higher score on one scale of impulsiveness than hyperprolactinemic patients not treated or 10 patients with a normal prolactin [<a href="#rid31">31</a>]. In an uncontrolled study of 308 patients who had lactotroph adenomas and were treated with cabergoline for at least three months, 17 percent developed an impulse control disorder [<a href="#rid32">32</a>]. The increased risk of impulse control disorders has also been described in up to 50 percent of patients taking dopamine agonists for Parkinson disease (See  <a class="medical medical_review" href="/d/html/4896.html" rel="external">"Initial pharmacologic treatment of Parkinson disease", section on 'Impulse control disorders'</a>.)</p><p class="headingAnchor" id="H361075770"><span class="h3">Valvular heart disease</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">Cabergoline</a> and pergolide have been associated with valvular heart disease in patients with Parkinson disease [<a href="#rid14">14,15</a>]. The association appears to be dose dependent, and the pergolide doses used for Parkinson disease were much higher than those used for hyperprolactinemia. In the United States, pergolide was voluntarily withdrawn from the market in March 2007 due to this risk [<a href="#rid17">17</a>]. </p><p>In contrast to the excess risk of cardiac valvulopathy associated with high-dose <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> use for Parkinson disease, most studies suggest that low-dose cabergoline for hyperprolactinemia is probably not<strong> </strong>associated with excess risk [<a href="#rid33">33-42</a>]. In one report of 50 patients with lactotroph adenoma treated with cabergoline, moderate tricuspid regurgitation was more frequent (54 percent) than in 50 age- and sex-matched subjects (18 percent) [<a href="#rid35">35</a>]. In a cross-sectional study, 62 patients who were treated with cabergoline were more likely to have valvular disease, primarily mild regurgitation, than patients who were treated with <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> (37.1 versus 17.5 percent, respectively) [<a href="#rid43">43</a>]. However, in a review of nine studies published through 2008, the majority did not demonstrate an increased risk of valvular regurgitation with cabergoline [<a href="#rid33">33</a>]. Most patients were using standard doses of cabergoline for hyperprolactinemia (0.5 to 1.5 mg/week).</p><p>Additional reassuring data come from a prospective study of 40 patients with newly diagnosed hyperprolactinemia treated with a median cumulative dose of 149 mg over five years [<a href="#rid44">44</a>]. Patients were evaluated by transthoracic echocardiography before initiating <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> and after 24 and 60 months of therapy; none of the patients developed significant valvulopathy.</p><p>One hundred and ninety-one of patients who were reported in one of the studies above [<a href="#rid42">42</a>] were followed for an additional median time of 34 months, during which time they took a median additional 232 mg of <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> and had a transthoracic echocardiogram at the beginning and end of the additional observation period. No association was found between the dose of cabergoline and the prevalence of a valvular abnormality [<a href="#rid45">45</a>].</p><p>However, new onset of valvular heart disease has been reported in a few patients taking <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a>. In one patient who was treated with 6 mg of cabergoline a week, serial echocardiograms showed no valvular disease when the cumulative dose was 3272 mg, but a thickened and restricted aortic valve when the cumulative dose was 4192 mg [<a href="#rid46">46</a>].</p><p>Based upon the available data, we suggest using the lowest dose of <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> necessary to lower prolactin to normal. We also suggest ordering cardiac ultrasonography approximately every two years in patients who take larger than typical doses of cabergoline (eg, greater than 2 mg per week). There are no available data for cabergoline use in patients with preexisting valvular heart disease. However, for patients with a lactotroph adenoma and mild valvular heart disease, we feel it is reasonable to use cabergoline therapy since the doses used in this setting have not been associated with an increased risk of valvular heart disease.</p><p>Withdrawal of therapy is discussed below. (See <a class="local">'Withdrawal of dopamine agonists'</a> below.)</p><p class="headingAnchor" id="H3847501948"><span class="h3">Cerebrospinal fluid rhinorrhea</span><span class="headingEndMark"> — </span>Cerebrospinal fluid rhinorrhea may occur during dopamine agonist treatment for very large lactotroph adenomas that extend inferiorly and invade the floor of the sella [<a href="#rid47">47,48</a>]. Although uncommon, early recognition and neurosurgical evaluation of this complication is important because of the potential risk of bacterial meningitis.</p><p class="headingAnchor" id="H361071100"><span class="h1">MICROADENOMAS</span></p><p class="headingAnchor" id="H361071649"><span class="h2">Initial therapy (dopamine agonists)</span><span class="headingEndMark"> — </span>Given the high rate of efficacy and low rate of side effects with dopamine agonists, as well as the consequences of hypogonadism, we recommend that these agents be used in patients with lactotroph microadenomas who have any degree of hypogonadism. Decreasing the size of the pituitary adenoma is <strong>not</strong> a treatment goal in these patients.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">Cabergoline</a> is the best initial choice in most circumstances because it is most likely to be effective and least likely to cause side effects. Our approach is consistent with the Endocrine Society hyperprolactinemia clinical guidelines [<a href="#rid2">2</a>]. The initial dose should be 0.25 mg twice a week or 0.5 mg once a week, if a patient finds that more convenient. Giving the dose at dinner or at bedtime reduces the chance of nausea or sleepiness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We now typically offer <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> to women who wish to become pregnant. <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">Bromocriptine</a> might theoretically be a better first choice because there is more evidence that it does not cause congenital anomalies [<a href="#rid49">49</a>], However, available data suggest that cabergoline is also safe in early pregnancy [<a href="#rid50">50,51</a>], and it has the other advantages over bromocriptine described above. (See  <a class="medical medical_review" href="/d/html/6629.html" rel="external">"Management of lactotroph adenoma (prolactinoma) before and during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> is used, we suggest a starting dose of 1.25 mg after dinner or at bedtime for one week, then increase to 1.25 mg twice a day (after breakfast and after dinner or at bedtime).</p><p></p><p class="headingAnchor" id="H361071655"><span class="h2">Response to therapy</span><span class="headingEndMark"> — </span>After one month of therapy, the patient should be evaluated for side effects and serum prolactin should be measured. Subsequent treatment depends upon the response:</p><p class="headingAnchor" id="H361071662"><span class="h3">Prolactin normalized</span><span class="headingEndMark"> — </span>If the serum prolactin concentration is normal and no side effects have occurred, the initial dose should be continued. In this setting, gonadal function will probably return within a few months. (See <a class="local">'Long-term follow-up'</a> below.)</p><p>Of note, in some patients, dopamine agonist therapy may result in restoration of normal gonadal function (eg, normal menstrual cycles in women) even if serum prolactin levels remain slightly high. In this case, the reproductive outcome (menstrual function) can be followed rather than the absolute prolactin level to determine treatment dose.</p><p>Similarly, when treating women with bothersome galactorrhea, the goal of therapy is to lower the serum prolactin low enough to resolve the galactorrhea. This may not require lowering prolactin into the normal range for the galactorrhea to remit.</p><p class="headingAnchor" id="H361071669"><span class="h3">Prolactin improved but not normal</span></p><p class="bulletIndent1"><span class="glyph">●</span>If the serum prolactin concentration has not decreased to normal but no side effects have occurred, the dose should be increased gradually to as much as 1.5 mg of <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> two or three times a week or 5 mg of <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> twice a day. Whatever dose results in a normal serum prolactin value should be continued. (See <a class="local">'Prolactin normalized'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> dose is increased above 2 mg per week, we suggest cardiac ultrasonography every two years in patients to monitor for valvular heart disease.</p><p></p><p class="headingAnchor" id="H361071682"><span class="h3">Intolerant or inadequate response</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>To initial therapy:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the serum prolactin concentration does not decrease sufficiently to restore normal gonadal function in response to <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> (if it was chosen as initial therapy) and if compliance seems good, changing to <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> may be effective. The cabergoline dose should then be adjusted until the serum prolactin concentration is normal. (See <a class="local">'Prolactin normalized'</a> above.)</p><p></p><p class="bulletIndent2">Approximately 25 percent of patients are resistant to <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> [<a href="#rid11">11,13</a>], and most (80 percent) can achieve normal prolactin concentrations with <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> therapy [<a href="#rid13">13,52</a>]. It is estimated that 10 percent of patients are resistant to cabergoline [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the patient cannot tolerate the first dopamine agonist administered because of side effects, another can be tried. In women, nausea can be avoided by vaginal administration [<a href="#rid53">53</a>], although other side effects cannot.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>To all </strong><strong>dopamine</strong><strong> agonists:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who do not respond to typical doses of dopamine agonists, eg, up to 2 mg of <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> a week, may respond to higher doses [<a href="#rid52">52</a>], but higher doses may be associated with higher risk of valvular heart disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If dopamine agonists have been unsuccessful or the patient cannot tolerate them, transsphenoidal surgery or ovulation induction with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate can be considered (for women wishing to become pregnant). For women not pursuing pregnancy, <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> and <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> replacement can be considered; men can consider <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> therapy. (See <a class="local">'Role of transsphenoidal surgery'</a> below and  <a class="medical medical_review" href="/d/html/7407.html" rel="external">"Overview of ovulation induction"</a> and <a class="local">'Treatment of women with estradiol'</a> below.)</p><p></p><p class="headingAnchor" id="H361071701"><span class="h4">Treatment of women with estradiol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">Estradiol</a>, along with a progestin, can be considered as sole therapy for the hypogonadism resulting from hyperprolactinemia in women who have lactotroph microadenomas but who cannot tolerate or do not respond to dopamine agonists and do not want to become pregnant (see  <a class="medical medical_review" href="/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)", section on 'Importance of estrogen therapy'</a>). Estradiol is also a reasonable option for women who have hypogonadism resulting from hyperprolactinemia due to other causes, including antipsychotic agents. (See  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia"</a> and <a class="local">'Drug-induced hyperprolactinemia'</a> below.)</p><p>Since <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> treatment might pose a slight risk of increasing the size of the adenoma, the serum prolactin concentration should be measured periodically in these patients. Estradiol should <strong>not</strong> be used as the sole treatment for lactotroph macroadenomas.</p><p><a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">Estradiol</a> and progestin can be administered separately in low doses as they would be for the treatment of hypogonadism of any etiology, or estrogen can be administered in the form of an oral contraceptive. (See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a>.)</p><p class="headingAnchor" id="H361072517"><span class="h4">Treatment of men with testosterone</span><span class="headingEndMark"> — </span>For men with hyperprolactinemia causing hypogonadism who cannot tolerate or who do not respond to dopamine agonists, <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> treatment can be considered for those who are not interested in fertility and human chorionic gonadotropin (hCG) for those who are. (See  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a> and  <a class="medical medical_review" href="/d/html/7463.html" rel="external">"Induction of fertility in males with secondary hypogonadism"</a>.)</p><p class="headingAnchor" id="H361071708"><span class="h4">Transsphenoidal surgery</span><span class="headingEndMark"> — </span>Transsphenoidal surgery should be considered in patients with microadenomas when dopamine agonist treatment has been unsuccessful in lowering the serum prolactin concentration, symptoms or signs due to hyperprolactinemia persist even after several months of treatment, and gonadal steroid replacement is not an option, eg, when pregnancy is desired. The role of surgery in patients with macroadenomas is reviewed below. (See <a class="local">'Role of transsphenoidal surgery'</a> below.)</p><p class="headingAnchor" id="H361071715"><span class="h2">Long-term follow-up</span><span class="headingEndMark"> — </span>Patients with microadenomas who achieve normal serum prolactin concentrations should be treated for at least one year. Serum prolactin measurements should be obtained at least every 12 months [<a href="#rid1">1,2</a>].</p><p>After approximately one year of treatment (if prolactin is normal), the dose can often be decreased. If the prolactin has been normal for two or more years and no adenoma is seen on magnetic resonance imaging (MRI), discontinuation of the drug can be considered. (See <a class="local">'Withdrawal of dopamine agonists'</a> below.)</p><p>Dopamine agonists should be stopped in women who become pregnant. (See  <a class="medical medical_review" href="/d/html/6629.html" rel="external">"Management of lactotroph adenoma (prolactinoma) before and during pregnancy", section on 'Fetal risk of dopamine agonist exposure'</a>.)</p><p class="headingAnchor" id="H361071866"><span class="h3">Withdrawal of dopamine agonists</span><span class="headingEndMark"> — </span>We suggest considering decreasing gradually and then discontinuing the dopamine agonist in the following situations:</p><p class="bulletIndent1"><span class="glyph">●</span>A patient who had idiopathic hyperprolactinemia (no pituitary mass at baseline) and whose serum prolactin decreased to low normal in response to dopamine agonist treatment. We suggest gradually decreasing the dose, as long as the prolactin remains within the normal range. If a patient has a normal prolactin for two years while taking a low dose (eg, 0.25 mg twice a week) of <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a>, we suggest a trial of discontinuation of the drug.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient who had hyperprolactinemia and a microadenoma prior to treatment in whom prolactin fell to normal and who has not had evidence of an adenoma by MRI for at least two years. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient had a macroadenoma prior to treatment, as long as the serum prolactin has been normal and no adenoma has been detectable by MRI for at least two years.</p><p></p><p>Our approach is consistent with that of the Endocrine Society clinical guidelines [<a href="#rid2">2</a>]. If the drug is discontinued, prolactin should be measured after three months and yearly thereafter. If the prolactin increases substantially (eg, to &gt;100 ng/mL), especially in a patient who originally had a macroadenoma, an MRI should be performed.</p><p>We recommend not stopping the dopamine agonist if the prolactin increases above normal while gradually decreasing the drug.</p><p>If serum prolactin increases after a withdrawal attempt, we suggest resuming <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> therapy at the same dose that previously kept the prolactin normal and decreased the adenoma size to undetectable.</p><p>Several studies have reported the consequences of discontinuation of dopamine agonist treatment in patients who have hyperprolactinemia. Recurrence of hyperprolactinemia and increase in adenoma size have been variable [<a href="#rid54">54-59</a>].</p><p>In one prospective study of 200 cabergoline-treated patients with hyperprolactinemia (25 with idiopathic hyperprolactinemia, 105 with microadenomas, and 70 with macroadenomas), therapy was withdrawn when serum prolactin concentrations were normal and MRI showed no adenoma (or &gt;50 percent reduction with no cavernous sinus invasion and &gt;5 mm distance from the optic chiasm) [<a href="#rid54">54</a>]. After two to five years of observation, the following results were seen:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperprolactinemia recurred in 24, 31, and 36 percent of patients with idiopathic hyperprolactinemia, microadenomas, and macroadenomas, respectively (eg, a remission rate [persistent normoprolactinemia] of 64 to 76 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adenoma regrowth was not seen in any patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperprolactinemia in patients with adenomas was more likely to recur if an adenoma remnant was seen on MRI than if it was not when treatment was stopped (78 versus 33 percent for macroadenomas, and 42 versus 26 percent for microadenomas).</p><p></p><p>Most patients with a macroadenoma remnant had adenoma recurrence by seven years of follow-up [<a href="#rid60">60</a>]. However, giant adenomas (&gt;3 cm) may behave more aggressively, as shown by case reports of rapid, substantial regrowth within weeks of discontinuation of dopamine agonist medication [<a href="#rid61">61,62</a>].</p><p>In contrast, a number of other studies report higher rates of recurrent hyperprolactinemia (eg, lower rates of remission) [<a href="#rid55">55,58,62</a>]. In a meta-analysis of 19 studies with a total of 743 patients, the overall rate of remission (persistent normoprolactinemia) after withdrawal of dopamine agonist therapy was only 21 percent (32, 21, and 16 percent for idiopathic hyperprolactinemia, microprolactinomas, and macroprolactinomas, respectively) [<a href="#rid59">59</a>]. Other findings included:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher rate of remission in studies in which <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> was used (35 percent in four studies) than in those in which <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> was used (20 percent in 12 studies).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher rates of remission in studies with treatment duration longer than 24 months (34 percent) compared with studies with shorter treatment duration (16 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher rate of remission in studies where a 50 percent tumor reduction was achieved in all patients before stopping therapy (55 percent remission rate was seen).</p><p></p><p>In summary, hyperprolactinemia may recur in a considerable number of patients after stopping dopamine agonist therapy. The probability of remission is best the longer the serum prolactin has been normal and no adenoma has been seen by MRI, preferably for at least two years.</p><p class="headingAnchor" id="H361077231"><span class="h3">Menopause</span><span class="headingEndMark"> — </span>After menopause, the drug can be discontinued and the serum prolactin concentration can be allowed to rise. Imaging should be performed if the value rises above 200 ng/mL to determine if the adenoma has increased to a clinically important size. If so, drug therapy should be resumed.</p><p class="headingAnchor" id="H361072832"><span class="h1">MACROADENOMAS</span></p><p class="headingAnchor" id="H361073759"><span class="h2">Initial therapy</span><span class="headingEndMark"> — </span>Treatment of patients with lactotroph macroadenomas, no matter how large or how severe the neurologic sequelae, should also be initiated with a dopamine agonist, starting with <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> [<a href="#rid2">2</a>], as described above for patients with microadenomas. (See <a class="local">'Microadenomas'</a> above.) Patients whose macroadenomas are largely cystic should also be treated initially with a dopamine agonist since this treatment shrinks most of these [<a href="#rid63">63</a>]. We titrate the dose up on the same schedule as for patients with microadenomas. Increasing the dose too quickly can increase the risk of side effects and lead to the erroneous conclusion that the patient is unable to tolerate the drug.</p><p class="headingAnchor" id="H886625398"><span class="h3">Titration of dose and monitoring</span><span class="headingEndMark"> — </span>The serum prolactin should be measured and the <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> dose should be increased every one to three months, if necessary, until the serum prolactin concentration becomes normal.</p><p>If vision was abnormal before therapy, it should be reassessed within one month, although improvement may occur within a few days. MRI should be repeated in 6 to 12 months to determine if the size of the adenoma has decreased.</p><p>In most patients with lactotroph macroadenomas:</p><p class="bulletIndent1"><span class="glyph">●</span>The size of the adenoma decreases to approximately the same degree as the serum prolactin concentration, although the relationship varies from patient to patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The decrease in size usually cannot be demonstrated until weeks or months after the prolactin secretion has decreased  (<a class="graphic graphic_diagnosticimage graphicRef86088" href="/d/graphic/86088.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The size of the adenoma can continue to decrease for years.</p><p></p><p>Once serum prolactin has normalized:</p><p class="bulletIndent1"><span class="glyph">●</span>If the clinical picture is stable (no evidence of adenoma growth on MRI and no symptoms such as headaches or visual symptoms), serum prolactin should be measured in six months, and if normal, it should then be measured yearly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum prolactin should be measured at any point if there are recurrent or new symptoms.</p><p></p><p class="headingAnchor" id="H886625404"><span class="h4">Candidates for stopping therapy</span><span class="headingEndMark"> — </span>If the serum prolactin concentration has been normal for at least one year and the adenoma has decreased markedly in size, the dose of the dopamine agonist can be decreased gradually, as long as the serum prolactin remains normal [<a href="#rid64">64</a>]. Discontinuation can be considered in those patients who had macroadenomas of modest size (eg, 1.0 to 1.5 cm), whose serum prolactin concentrations have been normal for more than two years, and whose adenomas can no longer be visualized by MRI for more than two years.</p><p>If the drug is discontinued, the prolactin concentration and the size of the adenoma by MRI must be monitored.</p><p>Discontinuation should probably <strong>not</strong> be considered if the adenoma was initially &gt;2 cm, if it can still be visualized by MRI during treatment, or if the prolactin has not become normal during treatment. The agonist should not be discontinued entirely, even after menopause, because hyperprolactinemia will probably recur and the adenoma may increase in size [<a href="#rid54">54,61,62</a>]. (See <a class="local">'Withdrawal of dopamine agonists'</a> above.)</p><p class="headingAnchor" id="H886625461"><span class="h4">Inadequate response or drug intolerance</span><span class="headingEndMark"> — </span>We recommend the following approach in patients who do not have a complete response to dopamine agonist therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> was tried first and the patient cannot tolerate it or the adenoma does not respond to it, <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> should be tried.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient cannot tolerate or the adenoma does not respond to agonist therapy, transsphenoidal surgery should be performed, and if a significant amount of adenoma tissue remains after surgery, radiation therapy should be administered (see  <a class="medical medical_review" href="/d/html/86684.html" rel="external">"Radiation therapy of pituitary adenomas"</a>). Surgery can also be considered for the woman who has a giant adenoma and is contemplating pregnancy. (See <a class="local">'Role of transsphenoidal surgery'</a> below.)</p><p></p><p class="headingAnchor" id="H361073030"><span class="h5">Role of transsphenoidal surgery</span><span class="headingEndMark"> — </span>Transsphenoidal surgery should be considered when:</p><p class="bulletIndent1"><span class="glyph">●</span>Dopamine agonist treatment has been unsuccessful in lowering the serum prolactin concentration or size of the adenoma, and symptoms or signs due to hyperprolactinemia or adenoma size persist after several months of treatment at high doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A woman has a giant lactotroph adenoma (eg, &gt;3 cm) and wishes to become pregnant even if the adenoma responds to a dopamine agonist. The rationale for this approach is that if the patient becomes pregnant and discontinues the agonist for the duration of pregnancy, the adenoma may increase to a clinically important size before delivery.</p><p></p><p>Surgery is usually successful in substantially reducing serum prolactin concentrations in patients with lactotroph adenomas, sometimes to normal [<a href="#rid65">65-68</a>]. It is a safer procedure when performed by an experienced surgeon [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Lactotroph adenomas'</a>.)</p><p>Surgery, however, has the following limitations:</p><p class="bulletIndent1"><span class="glyph">●</span>Not all of the adenoma tissue is excised in many patients, particularly those with macroadenomas. (See  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Lactotroph adenomas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The adenoma and hyperprolactinemia may recur within several years after surgery. (See  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Lactotroph adenomas'</a>.)</p><p></p><p>Complications are the same as may occur during and after transsphenoidal surgery for any kind of pituitary adenoma.</p><p class="headingAnchor" id="H361073286"><span class="h5">Postoperative radiation therapy</span><span class="headingEndMark"> — </span>Radiation is primarily used to prevent regrowth of residual tumor in a patient with a very large macroadenoma after transsphenoidal debulking of lactotroph adenomas that are resistant to <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a>. It should not be used for the primary treatment of patients with macroadenomas or at all for those with microadenomas. While radiation therapy (single dose or multiple fraction) appears to be effective in controlling growth of most pituitary macroadenomas, the effect on aggressive lactotroph adenomas that do not respond to dopamine agonists and cannot be entirely resected surgically is less well known. (See  <a class="medical medical_review" href="/d/html/86684.html" rel="external">"Radiation therapy of pituitary adenomas"</a>.)</p><p>Complications of radiation include transient nausea, lassitude, loss of taste and smell, loss of scalp hair at the radiation portals during and shortly after the treatment, and possible damage to the optic nerve and neurologic dysfunction [<a href="#rid1">1</a>]. There is also a 50 percent chance of loss of anterior pituitary hormone secretion during the subsequent 10 years [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H445458581"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>The management of lactotroph adenomas before, during, and after pregnancy is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/6629.html" rel="external">"Management of lactotroph adenoma (prolactinoma) before and during pregnancy"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">TREATMENT OF NONADENOMA CAUSES</span><span class="headingEndMark"> — </span>Treatment of hyperprolactinemia due to an abnormality other than a lactotroph adenoma varies depending on the cause:</p><p class="headingAnchor" id="H608703988"><span class="h2">Idiopathic hyperprolactinemia</span><span class="headingEndMark"> — </span>In a substantial number of patients whose serum prolactin concentration is between 20 and 100 ng/mL (100 mcg/L SI units), no cause can be found; they are considered to have idiopathic hyperprolactinemia. Although many of these patients may have microadenomas not visible on imaging studies, in most of them, the serum prolactin concentrations change little during follow-up for several years. Serum prolactin should be measured yearly. (See  <a class="medical medical_review" href="/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a>.)</p><p>In patients with idiopathic hyperprolactinemia (no pituitary mass at baseline) whose serum prolactin decreased to low-normal in response to dopamine agonist treatment, we suggest attempting to decrease the dose gradually, as long as the prolactin remains within the normal range. If a patient has a normal prolactin for two years while taking a low dose (eg, 0.25 mg of <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> twice a week), we suggest a trial of discontinuation of the drug. (See <a class="local">'Withdrawal of dopamine agonists'</a> above.)</p><p class="headingAnchor" id="H18"><span class="h2">Hypothalamic and pituitary disease</span><span class="headingEndMark"> — </span>Any disease in or near the hypothalamus or pituitary that interferes with the secretion of dopamine or its delivery to the hypothalamus can cause hyperprolactinemia, including tumors and infiltrative diseases of the hypothalamus, section of the hypothalamic-pituitary stalk (eg, due to head trauma or surgery), and adenomas of the pituitary other than lactotroph adenomas. If removal of the adenoma or mass is not possible, the hyperprolactinemia should be treated with a dopamine agonist.</p><p class="headingAnchor" id="H88725190"><span class="h2">Drug-induced hyperprolactinemia</span><span class="headingEndMark"> — </span>A number of drugs, especially antipsychotics and some antihypertensives (<a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="9635" href="/d/drug information/9635.html" rel="external">methyldopa</a>), can cause hyperprolactinemia  (<a class="graphic graphic_algorithm graphicRef134594" href="/d/graphic/134594.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef75914" href="/d/graphic/75914.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/6626.html" rel="external">"Causes of hyperprolactinemia", section on 'Drug induced'</a>.)</p><p>If the hyperprolactinemia is asymptomatic, no treatment is necessary. If symptoms are present and the hyperprolactinemia is due to a drug other than an antipsychotic agent, we suggest discontinuing the drug as a trial. If discontinuation is not feasible, options include switching to a drug with a similar action that does not cause hyperprolactinemia, adding <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> or <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> for the hypogonadal symptoms and/or low bone mass, or cautious administration of a dopamine agonist, as described in the following section.</p><p class="headingAnchor" id="H19"><span class="h3">Antipsychotic drug use</span><span class="headingEndMark"> — </span>If an antipsychotic drug is causing hyperprolactinemia and hypogonadism but cannot be discontinued because it is essential, several possible treatment options can be considered  (<a class="graphic graphic_algorithm graphicRef134594" href="/d/graphic/134594.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Addition of a dopamine agonist. This option should be undertaken <strong>very</strong> cautiously in consultation with the treating psychiatrist since it might counteract the dopamine antagonist property of the antipsychotic drug.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Change to an antipsychotic drug that does not raise prolactin, such as <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>. This course should only be considered in conjunction with the treating psychiatrist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Addition of the antipsychotic drug <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> to the existing antipsychotic drug. This drug has both dopamine agonist and antagonist properties and dampens hyperprolactinemia when added to other antipsychotic drugs such as <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Addition of <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> and progestin to treat the estradiol deficiency and prevent bone loss in women and <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> to treat testosterone deficiency in men. This approach will not treat the hyperprolactinemia.</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Hypothyroidism</span><span class="headingEndMark"> — </span>If hyperprolactinemia is solely the result of hypothyroidism, it will remit as the hypothyroidism is corrected, so no other treatment is necessary. (See  <a class="medical medical_review" href="/d/html/6626.html" rel="external">"Causes of hyperprolactinemia", section on 'Hypothyroidism'</a> and  <a class="medical medical_review" href="/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults"</a>.)</p><p class="headingAnchor" id="H2993299"><span class="h2">Macroprolactinemia</span><span class="headingEndMark"> — </span>Macroprolactinemia or "big prolactin" is a benign condition that does<strong> not </strong>require treatment, as it does not result from a pituitary adenoma or cause hypogonadism.</p><p>Macroprolactin is an umbrella term used to describe nonbioactive prolactin isoforms, usually composed of a prolactin monomer and an immunoglobulin G (IgG) molecule. These isoforms are clinically nonreactive and range in size from approximately 150 to 170 kD (the most common form of native prolactin in serum is 23 kD in size).</p><p>Macroprolactinemia is sometimes misdiagnosed and treated as ordinary hyperprolactinemia. Misdiagnosis can be avoided by asking the laboratory to pretreat the serum with polyethylene glycol to precipitate the macroprolactin before the immunoassay for prolactin. (See  <a class="medical medical_review" href="/d/html/6626.html" rel="external">"Causes of hyperprolactinemia", section on 'Macroprolactinemia'</a>.)</p><p class="headingAnchor" id="H2075694514"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116386.html" rel="external">"Society guideline links: Hyperprolactinemia/prolactinoma"</a>.)</p><p class="headingAnchor" id="H1180079"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15891.html" rel="external">"Patient education: Prolactinoma (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2182.html" rel="external">"Patient education: High prolactin levels and prolactinomas (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lactotroph microadenomas</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dopamine</strong><strong> agonist therapy</strong> – For patients with lactotroph microadenomas and any degree of hypogonadism, we recommend initial treatment with a dopamine agonist (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We also use dopamine agonist therapy in women with hyperprolactinemia and normal menstrual cycles if they have bothersome galactorrhea. (See <a class="local">'Microadenomas'</a> above and <a class="local">'Premenopausal women'</a> above.)</p><p></p><p class="bulletIndent2">We suggest <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> over <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> because it is more likely to be effective and less likely to cause side effects (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Choice of drug'</a> above.)</p><p></p><p class="bulletIndent2">For patients who require higher than usual doses of <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> (eg, greater than 2 mg per week), cardiac ultrasonography should be performed every two years. (See <a class="local">'Valvular heart disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fertility</strong> – The management of women with lactotroph microadenomas seeking fertility is reviewed separately. (See  <a class="medical medical_review" href="/d/html/6629.html" rel="external">"Management of lactotroph adenoma (prolactinoma) before and during pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Estradiol</strong><strong> and progestin therapy</strong> – In premenopausal women who have lactotroph microadenomas causing hyperprolactinemia and hypogonadism, but who cannot tolerate or do not respond to dopamine agonists and do not want to become pregnant, we suggest <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> and progestin replacement to prevent bone loss (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Treatment of women with estradiol'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lactotroph macroadenomas</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy with </strong><strong>dopamine</strong><strong> agonists</strong> – For patients with lactotroph macroadenomas, no matter how large or how severe the neurologic consequences, we recommend initial treatment with a dopamine agonist (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Dosing is the same as that for microadenomas. (See <a class="local">'Microadenomas'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transsphenoidal surgery</strong> – Transsphenoidal surgery is a reasonable option for patients in whom dopamine agonist treatment has been unsuccessful in reducing the serum prolactin concentration or size of the macroadenoma, or when symptoms or signs due to hyperprolactinemia or adenoma size do not improve. (See <a class="local">'Role of transsphenoidal surgery'</a> above.)</p><p></p><p class="bulletIndent2">In patients with large macroadenomas who have undergone transsphenoidal debulking and in whom considerable residual adenoma remains in a location not readily accessible to surgery, we suggest radiation therapy to prevent regrowth of residual adenoma (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We do not use radiation therapy for the primary treatment of patients with macroadenomas or at all for those with microadenomas. (See <a class="local">'Postoperative radiation therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperprolactinemia due to antipsychotic agents</strong> – We use gonadal steroid replacement therapy in patients with hyperprolactinemia and hypogonadism due to antipsychotic agents (estradiol-progestin in women and <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> in men) if addition of a dopamine agonist is not possible or if a satisfactory antipsychotic regimen that does not cause hyperprolactinemia cannot be found  (<a class="graphic graphic_algorithm graphicRef134594" href="/d/graphic/134594.html" rel="external">algorithm 1</a>). (See <a class="local">'Antipsychotic drug use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Can </strong><strong>dopamine</strong><strong> agonist therapy be discontinued?</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with lactotroph adenomas who have had no evidence of the adenoma by MRI for at least two years and have had a normal prolactin while taking a low dose of dopamine agonist for at least two years, we suggest a trial of stopping the drug (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Withdrawal of dopamine agonists'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We use a similar approach for patients with idiopathic hyperprolactinemia (negative MRI) who have had a normal prolactin for at least two years on a low dose of dopamine agonist. (See <a class="local">'Withdrawal of dopamine agonists'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65:265.</a></li><li><a class="nounderline abstract_t">Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273.</a></li><li><a class="nounderline abstract_t">Melmed S. Pituitary-Tumor Endocrinopathies. N Engl J Med 2020; 382:937.</a></li><li><a class="nounderline abstract_t">Schlechte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989; 68:412.</a></li><li><a class="nounderline abstract_t">Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril 1987; 48:67.</a></li><li><a class="nounderline abstract_t">Carter JN, Tyson JE, Tolis G, et al. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978; 299:847.</a></li><li><a class="nounderline abstract_t">Buvat J, Lemaire A, Buvat-Herbaut M, et al. Hyperprolactinemia and sexual function in men. Horm Res 1985; 22:196.</a></li><li><a class="nounderline abstract_t">Buvat J. Hyperprolactinemia and sexual function in men: a short review. Int J Impot Res 2003; 15:373.</a></li><li><a class="nounderline abstract_t">Vance ML, Evans WS, Thorner MO. Drugs five years later. Bromocriptine. Ann Intern Med 1984; 100:78.</a></li><li><a class="nounderline abstract_t">Wang AT, Mullan RJ, Lane MA, et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev 2012; 1:33.</a></li><li><a class="nounderline abstract_t">Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994; 331:904.</a></li><li><a class="nounderline abstract_t">Biller BM, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81:2338.</a></li><li><a class="nounderline abstract_t">Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84:2518.</a></li><li><a class="nounderline abstract_t">Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29.</a></li><li><a class="nounderline abstract_t">Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356:39.</a></li><li><a class="nounderline abstract_t">Kleinberg DL, Boyd AE 3rd, Wardlaw S, et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983; 309:704.</a></li><li class="breakAll">US Food and Drug Administration. FDA announces voluntary withdrawal of pergolide products (March 29, 2007). http://www.fda.gov/newsevents/newsroom/pressannouncements/2007/ucm108877.htm (Accessed on August 01, 2012).</li><li><a class="nounderline abstract_t">Vance ML, Lipper M, Klibanski A, et al. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Intern Med 1990; 112:668.</a></li><li><a class="nounderline abstract_t">Di Sarno A, Landi ML, Marzullo P, et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 2000; 53:53.</a></li><li><a class="nounderline abstract_t">Schultz PN, Ginsberg L, McCutcheon IE, et al. Quinagolide in the management of prolactinoma. Pituitary 2000; 3:239.</a></li><li><a class="nounderline abstract_t">Tindall GT, Kovacs K, Horvath E, Thorner MO. Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 1982; 55:1178.</a></li><li><a class="nounderline abstract_t">Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60:698.</a></li><li><a class="nounderline abstract_t">van der Lely AJ, Brownell J, Lamberts SW. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991; 72:1136.</a></li><li><a class="nounderline abstract_t">Moster ML, Savino PJ, Schatz NJ, et al. Visual function in prolactinoma patients treated with bromocriptine. Ophthalmology 1985; 92:1332.</a></li><li><a class="nounderline abstract_t">Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997; 82:3574.</a></li><li><a class="nounderline abstract_t">De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998; 138:286.</a></li><li><a class="nounderline abstract_t">De Rosa M, Zarrilli S, Vitale G, et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004; 89:621.</a></li><li><a class="nounderline abstract_t">Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 2004; 89:1704.</a></li><li><a class="nounderline abstract_t">Warfield A, Finkel DM, Schatz NJ, et al. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function. Ann Intern Med 1984; 101:783.</a></li><li><a class="nounderline abstract_t">Kletzky OA, Vermesh M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertil Steril 1989; 51:269.</a></li><li><a class="nounderline abstract_t">Barake M, Evins AE, Stoeckel L, et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary 2014; 17:150.</a></li><li><a class="nounderline abstract_t">Dogansen SC, Cikrikcili U, Oruk G, et al. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. J Clin Endocrinol Metab 2019; 104:2527.</a></li><li><a class="nounderline abstract_t">Valassi E, Klibanski A, Biller BM. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010; 95:1025.</a></li><li><a class="nounderline abstract_t">Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008; 93:3348.</a></li><li><a class="nounderline abstract_t">Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008; 93:3777.</a></li><li><a class="nounderline abstract_t">Wakil A, Rigby AS, Clark AL, et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008; 159:R11.</a></li><li><a class="nounderline abstract_t">Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009; 12:153.</a></li><li><a class="nounderline abstract_t">Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 2009; 70:104.</a></li><li><a class="nounderline abstract_t">Devin JK, Lakhani VT, Byrd BF 3rd, Blevins LS Jr. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract 2008; 14:672.</a></li><li><a class="nounderline abstract_t">Lafeber M, Stades AM, Valk GD, et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol 2010; 162:667.</a></li><li><a class="nounderline abstract_t">Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf) 2010; 73:369.</a></li><li><a class="nounderline abstract_t">Drake WM, Stiles CE, Howlett TA, et al. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab 2014; 99:90.</a></li><li><a class="nounderline abstract_t">Budayr A, Tan TC, Lo JC, et al. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. BMC Endocr Disord 2020; 20:25.</a></li><li><a class="nounderline abstract_t">Auriemma RS, Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol 2013; 169:359.</a></li><li><a class="nounderline abstract_t">Drake WM, Stiles CE, Bevan JS, et al. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. J Clin Endocrinol Metab 2016; 101:4189.</a></li><li><a class="nounderline abstract_t">Caputo C, Prior D, Inder WJ. The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening. J Endocr Soc 2018; 2:965.</a></li><li><a class="nounderline abstract_t">Leong KS, Foy PM, Swift AC, et al. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf) 2000; 52:43.</a></li><li><a class="nounderline abstract_t">Davis JR, Sheppard MC, Heath DA. Giant invasive prolactinoma: a case report and review of nine further cases. Q J Med 1990; 74:227.</a></li><li><a class="nounderline abstract_t">Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA 1982; 247:1589.</a></li><li><a class="nounderline abstract_t">Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10:333.</a></li><li><a class="nounderline abstract_t">Ricci E, Parazzini F, Motta T, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002; 16:791.</a></li><li><a class="nounderline abstract_t">Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008; 93:4721.</a></li><li><a class="nounderline abstract_t">Motta T, de Vincentiis S, Marchini M, et al. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. Fertil Steril 1996; 65:440.</a></li><li><a class="nounderline abstract_t">Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 349:2023.</a></li><li><a class="nounderline abstract_t">Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002; 87:3578.</a></li><li><a class="nounderline abstract_t">Biswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 2005; 63:26.</a></li><li><a class="nounderline abstract_t">Colao A, Di Sarno A, Guerra E, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 2007; 67:426.</a></li><li><a class="nounderline abstract_t">Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 2009; 94:2428.</a></li><li><a class="nounderline abstract_t">Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95:43.</a></li><li><a class="nounderline abstract_t">Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27:485.</a></li><li><a class="nounderline abstract_t">Thorner MO, Perryman RL, Rogol AD, et al. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 1981; 53:480.</a></li><li><a class="nounderline abstract_t">van 't Verlaat JW, Croughs RJ. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 1991; 34:175.</a></li><li><a class="nounderline abstract_t">Faje A, Chunharojrith P, Nency J, et al. Dopamine Agonists Can Reduce Cystic Prolactinomas. J Clin Endocrinol Metab 2016; 101:3709.</a></li><li><a class="nounderline abstract_t">Liuzzi A, Dallabonzana D, Oppizzi G, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985; 313:656.</a></li><li><a class="nounderline abstract_t">Feigenbaum SL, Downey DE, Wilson CB, Jaffe RB. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. J Clin Endocrinol Metab 1996; 81:1711.</a></li><li><a class="nounderline abstract_t">Randall RV, Laws ER Jr, Abboud CF, et al. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clin Proc 1983; 58:108.</a></li><li><a class="nounderline abstract_t">Serri O, Rasio E, Beauregard H, et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 1983; 309:280.</a></li><li><a class="nounderline abstract_t">Schlechte JA, Sherman BM, Chapler FK, VanGilder J. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J Clin Endocrinol Metab 1986; 62:1296.</a></li><li><a class="nounderline abstract_t">Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40:225.</a></li><li><a class="nounderline abstract_t">Snyder PJ, Fowble BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986; 81:457.</a></li><li><a class="nounderline abstract_t">Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 2009; 107:218.</a></li></ol></div><div id="topicVersionRevision">Topic 6630 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886971" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296991" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32130815" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pituitary-Tumor Endocrinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2918052" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The natural history of untreated hyperprolactinemia: a prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3595916" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The natural history of untreated microprolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/211411" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prolactin-screening tumors and hypogonadism in 22 men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4054839" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hyperprolactinemia and sexual function in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14562140" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hyperprolactinemia and sexual function in men: a short review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6229205" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Drugs five years later. Bromocriptine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22828169" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of hyperprolactinemia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7915824" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8964874" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10404830" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202453" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dopamine agonists and the risk of cardiac-valve regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202454" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Valvular heart disease and the use of dopamine agonists for Parkinson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6888442" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6888442" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1970714" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931080" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11788012" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Quinagolide in the management of prolactinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6752167" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3882737" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1673685" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4069600" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Visual function in prolactinoma patients treated with bromocriptine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360509" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9539303" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764772" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070934" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6497193" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2912773" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23504371" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30848825" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20130078" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559921" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682513" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625690" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18594989" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19128367" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18996784" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20071478" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20550538" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24187407" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32075620" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824978" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27571182" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30083627" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651752" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2385731" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Giant invasive prolactinoma: a case report and review of nine further cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7062462" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Surveillance of bromocriptine in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8829257" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pregnancy outcome after treatment with the ergot derivative, cabergoline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401507" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pregnancy outcome after cabergoline treatment in early weeks of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18812485" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8566276" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14627787" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161478" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963057" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573902" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19336508" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880787" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16705142" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Advances in the treatment of prolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7263835" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2036725" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27459530" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Dopamine Agonists Can Reduce Cystic Prolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4022058" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Low doses of dopamine agonists in the long-term treatment of macroprolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8626821" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6681646" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6866052" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3084539" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9007854" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3092668" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hypopituitarism following radiation therapy of pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038534" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
